Back to top
more

Precision BioSciences (DTIL)

(Delayed Data from NSDQ)

$8.74 USD

8.74
11,645

+0.13 (1.51%)

Updated Aug 16, 2024 02:09 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (74 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for DTIL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Precision BioSciences, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 117 190 144 90 181
Receivables 1 1 0 10 1
Notes Receivable 12 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 7 9 18 6 12
Total Current Assets 136 199 162 106 194
Net Property & Equipment 6 20 25 35 40
Investments & Advances 3 5 7 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 1 2 1 1
Deposits & Other Assets 5 10 12 2 1
Total Assets 160 238 212 150 235
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 3 1 1 1 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 7 9 11 9 8
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 39 47 22 31 16
Total Current Liabilities 50 60 36 43 27
Mortgages 0 0 0 0 0
Deferred Taxes/Income 73 83 67 54 66
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 22 2 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 10 10 10 0 4
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 141 178 120 106 97
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 509 490 409 331 316
Retained Earnings -490 -428 -317 -286 -177
Other Equity 0 0 0 0 0
Treasury Stock 1 1 1 1 1
Total Shareholder's Equity 19 60 91 44 138
Total Liabilities & Shareholder's Equity 160 238 212 150 235
Total Common Equity 19 60 91 44 138
Shares Outstanding 4.10 3.60 2.00 1.70 1.60
Book Value Per Share 4.60 16.79 45.59 26.14 86.44

Fiscal Year End for Precision BioSciences, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 124 138 117 122 138
Receivables 0 0 1 4 1
Notes Receivable 12 12 12 12 0
Inventories 0 0 0 0 0
Other Current Assets 8 11 7 8 9
Total Current Assets 144 161 136 146 148
Net Property & Equipment 4 5 6 9 18
Investments & Advances 3 3 3 2 2
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 1 2
Deposits & Other Assets 6 7 5 6 8
Total Assets 166 185 160 164 182
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 22
Accounts Payable 1 1 3 1 1
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 4 2 7 5 6
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 26 29 39 43 25
Total Current Liabilities 33 33 50 51 56
Mortgages 0 0 0 0 0
Deferred Taxes/Income 27 75 73 74 78
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 24 10 11 10
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 91 148 141 135 148
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 524 519 509 503 500
Retained Earnings -448 -481 -490 -473 -465
Other Equity 0 0 0 0 0
Treasury Stock 1 1 1 1 1
Total Shareholder's Equity 75 37 19 29 34
Total Liabilities & Shareholder's Equity 166 185 160 164 182
Total Common Equity 75 37 19 29 34
Shares Outstanding 7.20 6.90 4.10 3.80 3.70
Book Value Per Share 10.38 5.39 4.60 7.65 9.20